Compare Amphastar Pharmaceuticals Inc (AMPH) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Morgan Stanley — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.44 (market cap $863.95M), while Morgan Stanley trades at $216.06 (market cap $338.50B). The key difference: Morgan Stanley is far larger — about 391.8× Amphastar Pharmaceuticals Inc's market cap, and Morgan Stanley pays a 2.14% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MS | |
|---|---|---|
Market Cap | $863.95M | $338.50B |
Sector | Health | Financials |
52-Week High | $30.81 | $228.42 |
52-Week Low | $16.87 | $143.88 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Morgan Stanley (MS) trades at $216.26, up 1.18% with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $66.0B in 2025, with net income margin expanding to 25.56%. The stock is supported by analyst consensus price target of $239.58 and recent news of leading Anthropic's IPO, indicating robust business momentum.
Outlook remains positive given earnings growth and institutional support, but risks include volatile cash flows and high debt levels. The stock offers upside to consensus targets, though investors should monitor interest expense impacts and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
